Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Nov;12(5):559–562. doi: 10.1128/aac.12.5.559

Growth Properties of Mecillinam-Resistant Bacterial Variants in Urine

J D Anderson 1, M A Adams 2, H M Webster 2, L Smith 2
PMCID: PMC429975  PMID: 200171

Abstract

Resistant variants are often formed when susceptible Enterobacteriaceae are grown in media containing mecillinam. These variants have not yet been detected in patients or identified as a cause of treatment failure in limited clinical trials. Mecillinam-resistant organisms were formed by 5 out of 13 urinary isolates of Enterobacteriaceae incubated in urine containing mecillinam. The mean generation time of these five variants in urine containing therapeutic concentrations of mecillinam was 3.2 times that of normal organisms in antibiotic-free urine. When three of these five resistant variants were subcultured in antibiotic-free urine, the generation time, morphology, and antibiotic susceptibility returned to normal. On antibiotic-free agar medium, all five mecillinam-resistant variants readily reverted to the “susceptible” form and were therefore more likely to be phenotypic rather than genotypic mutants. In a second series of experiments, the flushing effect of the bladder on the clearance of organisms was partly simulated by frequent subculture in urine. Under these conditions, the cell density of cultures of all bacteria remained high during 10 subcultures over 52 h. However, bacterial populations progressively decreased in urine containing mecillinam until none could be detected at 28 h or thereafter. The slow growth rate of mecillinam-resistant variants may explain why detectable numbers of these organisms fail to colonize the urinary tract during treatment. Other factors may reinforce the postulated effect of the reduced growth rate in vivo.

Full text

PDF
559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. D., Adams M. A., Barrington J. C., Spence W. N., Sheperd C. A. Comparison of the epidemiology of bacterial resistance to mecillinam and ampicillin. Antimicrob Agents Chemother. 1976 Dec;10(6):872–877. doi: 10.1128/aac.10.6.872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson J. D., Adams M. A., Wilson L. C., Shepherd C. A. Studies on the effect of mecillinam upon Micrococcaceae and faecal streptococci under conditions simulating urinary tract infection. J Antimicrob Chemother. 1976 Dec;2(4):351–361. doi: 10.1093/jac/2.4.351. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. D. The relevance of urine and serum antibacterial activity to the treatment of urinary tract infections. J Antimicrob Chemother. 1976 Sep;2(3):226–228. doi: 10.1093/jac/2.3.226. [DOI] [PubMed] [Google Scholar]
  4. Anderson J. D., Warner M., Forshaw H. L. Studies on the effect of amoxycillin and ampicillin on Enterobacteriaceae in an experimental model of urinary infection. J Antimicrob Chemother. 1975 Jun;1(2):197–204. doi: 10.1093/jac/1.2.197. [DOI] [PubMed] [Google Scholar]
  5. Bentzen A. J., Vejlsgaard R., Jacobsen J., Tybring L. Clinical evaluation of a novel beta-lactam antibiotic: pivmecillinam (FL 1039). Infection. 1975;3(3):154–160. doi: 10.1007/BF01641339. [DOI] [PubMed] [Google Scholar]
  6. COX C. E., HINMAN F., Jr Experiments with induced bacteriuria, vesical emptying and bacterial growth on the mechanism of bladder defense to infection. J Urol. 1961 Dec;86:739–748. doi: 10.1016/S0022-5347(17)65257-1. [DOI] [PubMed] [Google Scholar]
  7. Christoffersen J. C., Iversen H. G., Jacobsen J., Korner B., Petersen H. K., Rasmussen F., Tybring L. FL 1039 in bacteriuria following prostatectomy. A double-blind comparison with pivampicillin and placebo. Scand J Urol Nephrol. 1974;8(3):185–192. doi: 10.3109/00365597409132127. [DOI] [PubMed] [Google Scholar]
  8. Clarke P. D., Geddes A. M., McGhie D., Wall J. C. Mecillinam: a new antibiotic for enteric fever. Br Med J. 1976 Jul 3;2(6026):14–15. doi: 10.1136/bmj.2.6026.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Drasar B. S., Shiner M., McLeod G. M. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology. 1969 Jan;56(1):71–79. [PubMed] [Google Scholar]
  10. Greenwood D., O'Grady F. FL 1060: a new beta-lactam antibiotic with novel properties. J Clin Pathol. 1973 Jan;26(1):1–6. doi: 10.1136/jcp.26.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Knothe H. Der Einfluss von Pivmecillinam auf die Darmflora des Menschen. Arzneimittelforschung. 1976;26(3):427–431. [PubMed] [Google Scholar]
  12. Lund F., Tybring L. 6 -amidinopenicillanic acids--a new group of antibiotics. Nat New Biol. 1972 Apr 5;236(66):135–137. doi: 10.1038/newbio236135a0. [DOI] [PubMed] [Google Scholar]
  13. Matsuhashi S., Kamiryo T., Blumberg P. M., Linnett P., Willoughby E., Strominger J. L. Mechanism of action and development of resistance to a new amidino penicillin. J Bacteriol. 1974 Feb;117(2):578–587. doi: 10.1128/jb.117.2.578-587.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neu H. C. Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother. 1976 May;9(5):793–799. doi: 10.1128/aac.9.5.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reeves D. S., Wise R., Bywater M. J. A laboratory evaluation of a novel (beta-lactam antibiotic mecillinam. J Antimicrob Chemother. 1975 Sep;1(3):337–344. doi: 10.1093/jac/1.3.337. [DOI] [PubMed] [Google Scholar]
  16. Roholt K., Nielsen B., Kristensen Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy. 1975;21(3-4):146–166. doi: 10.1159/000221856. [DOI] [PubMed] [Google Scholar]
  17. Tybring L. Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: in vitro evaluation. Antimicrob Agents Chemother. 1975 Sep;8(3):266–270. doi: 10.1128/aac.8.3.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tybring L., Melchior N. H. Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro. Antimicrob Agents Chemother. 1975 Sep;8(3):271–276. doi: 10.1128/aac.8.3.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Verrier Jones E. R., Asscher A. W. Treatment of recurrent bacteriuria with pivmecillinam (FL 1039). J Antimicrob Chemother. 1975 Jun;1(2):193–196. doi: 10.1093/jac/1.2.193. [DOI] [PubMed] [Google Scholar]
  20. Williams J. D., Andrews J., Mitchard M., Kendall M. J. Bacteriology and pharmacokinetics of the new amidino penicillin-mecillinam. J Antimicrob Chemother. 1976 Mar;2(1):61–69. doi: 10.1093/jac/2.1.61. [DOI] [PubMed] [Google Scholar]
  21. Wise R., Reeves D. S., Symonds J. M., Wilkinson P. J. A clinical investigation of pivmecillinam. A novel beta-lactam antibiotic in the treatment of urinary tract infections. Chemotherapy. 1976;22(5):335–339. doi: 10.1159/000221942. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES